|
|
|
 |
|
 |
 |
|||
Company News
|
Amgen to Acquire Micromet
Acquisition Includes a Novel Cancer Treatment in Clinical Trials for Hematologic Malignancies
Micromet's Proprietary BiTE® Platform has Potential to Improve Treatment in Multiple Tumor Types All-Cash Transaction Values Micromet at $1.16 Billion
California, USA, 30 January 2012
- THOUSAND OAKS, Calif., and ROCKVILLE, Md., Jan. 26, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Micromet, Inc. (NASDAQ:MITI) today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development (R&D) center in Munich and headquarters in Rockville, Md., for $11 per share in cash. The transaction, which values Micromet at approximately $1.16 billion, was unanimously approved by both the Amgen and Micromet Boards of Directors.
top
CELGENE TO ACQUIRE AVILA THERAPEUTICS
Oral Btk inhibitor AVL-292 offers promising potential for treatment of B-cell diseases. Avilomics™ Platform enhances drug discovery capabilities
Summit, NJ and Bedford, MA, 26 January 2012
top
Prosensa Raises €23 Million in New Equity Financing Led by New Enterprise Associates
Leiden, The Netherlands, 25 January 2012
top
SFJ PHARMA LTD. II, ANNOUNCES AGREEMENT WITH PFIZER TO DEVELOP AXITINIB FOR ADJUVANT TREATMENT OF RENAL CELL CARCINOMA
San Francisco, 09 January 2012
top
|
Archive:
|
|||||||||||||||||||||||||||||||||||||||||
